LA SB169

Clarifies that clinical utility for biomarker testing is demonstrated when a test meets any one of the criteria already listed in existing law (R.S. 22:1028.5)

Prohibits health coverage plans from denying coverage for biomarker tests based on laboratory classifications or credentialing standards unrelated to the actual performance of the covered test

Requires health plans to provide biomarker testing coverage in a manner that limits disruptions in care, including avoiding the need for multiple biopsies or biospecimen samples

Establishes that biomarker testing coverage requirements (R.S. 22:1028.5) prevail over genetic cancer screening requirements (R.S. 22:1028.3) in cases of conflict between the two statutes

Becomes effective upon the governor's signature or lapse of time for gubernatorial action